Want to see TSE:DOSE full AI Analyst Report?

Rapid Dose Therapeutics Corp (DOSE) Price & Analysis

8 Followers

DOSE Stock Chart & Stats

C$0.14

C$0.02(6.67%)

At close: Jan 08 4:00 PM EST

C$0.14

C$0.02(6.67%)

Day’s Range― - ―

52-Week RangeC$0.08 - C$0.20

Previous CloseN/A

Volume31.00K

Average Volume (3M)36.09K

Market Cap

C$14.19M

Enterprise ValueC$18.72M

Total Cash (Recent Filing)C$11.55K

Total Debt (Recent Filing)C$5.32M

Price to Earnings (P/E)―

Beta0.37

Next Earnings

Jul 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding135,181,840

10 Day Avg. Volume35,351

30 Day Avg. Volume36,089

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)-2.78

Price to Sales (P/S)7.19

P/FCF Ratio-73.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Drug-delivery PlatformRapid Dose’s oral thin‑film platform is a durable business model advantage: sublingual/buccal formats target rapid, non‑swallow dosing across therapeutic and consumer‑health applications. A platform technology can drive recurring licensing, formulation work, and differentiated product pipelines over multiple years.

Demonstrated Revenue Growth PotentialA historical revenue growth rate of ~33% indicates prior traction and market demand for the company’s offerings. This demonstrates scalable commercial potential and product adoption capacity that, if execution and commercialization improve, supports sustainable revenue expansion over a multi‑quarter horizon.

Improving Cash Burn / Cost ControlA materially smaller cash burn in the latest year signals improved cost discipline and operational efficiency. If sustained, lower ongoing cash requirements extend runway, reduce near‑term refinancing pressure and increase the chance to reach commercial inflection points without frequent dilutive financings.

Bears Say

Stressed Balance Sheet And Negative EquityPersistent negative shareholders’ equity and rising debt materially weaken financial flexibility. Negative equity limits conventional borrowing capacity, increases refinancing and dilution risk, and constrains the company’s ability to fund R&D or commercialization initiatives without adverse capital‑structure outcomes over the medium term.

Ongoing Negative Cash Generation And Financing DependenceConsistently negative operating and free cash flow make the company dependent on external capital to sustain operations. This structural funding need elevates dilution risk and can limit strategic flexibility, forcing tradeoffs between R&D, commercialization and balance‑sheet repair over coming quarters.

Volatile And Declining Revenue With Negative MarginsHighly volatile revenue combined with a recent ~29% decline and negative gross profit signals weak unit economics and unstable demand. Structural unprofitability at gross and operating levels undermines scale economics and raises questions about the durability of the business model absent meaningful margin improvement or stable revenue streams.

Rapid Dose Therapeutics Corp News

Rapid Dose Therapeutics Upgrades Burlington Plant for Global Pharma and Cannabis Growth

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an update. Rapid Dose Therapeutics has begun clean room...

3M ago

Rapid Dose Therapeutics to Pay High-Interest Note Obligations in Shares

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has shared an announcement. Rapid Dose Therapeutics Corp. has announced it...

4M ago

Rapid Dose Therapeutics Details 2026 Strategy and Global Expansion Drive

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an update. Rapid Dose Therapeutics outlined a 2026 strategic...

4M ago

Rapid Dose Wins Key Indian Patent for QuickStrip Nicotine Oral Film

An announcement from Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) is now available. Rapid Dose Therapeutics has secured...

5M ago

Rapid Dose Therapeutics Advances Cannabinoid Studies for QuickStrip Drug Delivery Platform

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has issued an announcement. Rapid Dose Therapeutics has provided an update...

5M ago

Rapid Dose Therapeutics Lists on U.S. OTCQB to Broaden Investor Access

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an update. Rapid Dose Therapeutics Corp., a Canadian biotechnology...

5M ago

Rapid Dose Therapeutics Enters Brazil’s Medical Cannabis Market With QuickStrip Launch

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has issued an update. Rapid Dose Therapeutics has launched its co-branded...

5M ago

Rapid Dose Therapeutics Pays Convertible Note Interest in Shares

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an announcement. Rapid Dose Therapeutics Corp. will issue 362,708...

7M ago

Rapid Dose Therapeutics Extends Convertible Notes Maturity Date

An update from Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) is now available. Rapid Dose Therapeutics Corp. announced...

8M ago

Rapid Dose Therapeutics Extends Nicotine Partnership and Advances NicStrip™ Commercialization

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an announcement. Rapid Dose Therapeutics Corp. has announced a...

9M ago

DOSE FAQ

What was Rapid Dose Therapeutics Corp’s price range in the past 12 months?

Rapid Dose Therapeutics Corp lowest stock price was C$0.08 and its highest was C$0.20 in the past 12 months.

What is Rapid Dose Therapeutics Corp’s market cap?

Rapid Dose Therapeutics Corp’s market cap is C$14.19M.

When is Rapid Dose Therapeutics Corp’s upcoming earnings report date?

Rapid Dose Therapeutics Corp’s upcoming earnings report date is Jul 24, 2026 which is tomorrow.

How were Rapid Dose Therapeutics Corp’s earnings last quarter?

Currently, no data Available

Is Rapid Dose Therapeutics Corp overvalued?

According to Wall Street analysts Rapid Dose Therapeutics Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rapid Dose Therapeutics Corp pay dividends?

Rapid Dose Therapeutics Corp does not currently pay dividends.

What is Rapid Dose Therapeutics Corp’s EPS estimate?

Rapid Dose Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rapid Dose Therapeutics Corp have?

Rapid Dose Therapeutics Corp has 135,181,840 shares outstanding.

What happened to Rapid Dose Therapeutics Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Rapid Dose Therapeutics Corp?

Currently, no hedge funds are holding shares in TSE:DOSE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Rapid Dose Therapeutics Corp

Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.